Msd Partners, L.P. Finch Therapeutics Group, Inc. Transaction History

Msd Partners, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.36 - $56.4 $84,705 - $13.3 Million	-235,294 Reduced 60.53%	153,397 $73,000
Q1 2022 Jun 22, 2023	SELL	$5.02 - $10.47 $3.9 Million - $8.14 Million	-777,382 Reduced 66.67%	388,691 $1.96 Million
Q4 2021 Jun 22, 2023	BUY	$8.95 - $16.88 $6.96 Million - $13.1 Million	777,382 Added 200.0%	1,166,073 $11.6 Million
Q3 2021 Jun 22, 2023	BUY	$12.2 - $16.75 $1.87 Million - $2.57 Million	153,397 Added 65.19%	388,691 $5.05 Million
Q3 2021 Nov 15, 2021	BUY	$12.2 - $16.75 $1.87 Million - $2.57 Million	153,397 Added 65.19%	388,691 $5.05 Million
Q2 2021 Jun 22, 2023	BUY	$12.03 - $17.51 $985,220 - $1.43 Million	81,897 Added 53.39%	235,294 $3.31 Million
Q2 2021 Aug 16, 2021	SELL	$12.03 - $17.51 $1.85 Million - $2.69 Million	-153,397 Reduced 39.47%	235,294 $3.31 Million
Q1 2021 May 17, 2021	BUY	$15.54 - $21.32 $6.04 Million - $8.29 Million	388,691 New	388,691 $6.28 Million

Ticker FNCH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,688,400
Market Cap $525M
Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides diffi...

Get notified when there are updates to the investment portfolio of Msd Partners, L.P., based on Form 13F filings with the SEC.

Stay updated on Msd Partners, L.P. with notifications on news.